Platinum
- Generic Name
- Platinum
- Drug Type
- Small Molecule
- Chemical Formula
- Pt
- CAS Number
- 7440-06-4
- Unique Ingredient Identifier
- 49DFR088MY
- Background
Platinum is under investigation for the treatment of Metastatic Breast Cancer, Non-small Cell Lung Cancer, Gastric Large Cell Neuroendocrine Carcinoma, Colorectal Large Cell Neuroendocrine Carcinoma, and Pancreatic Large Cell Neuroendocrine Carcinoma, among others. Platinum has been investigated for the treatment and supportive care of Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Primary Cancer, Non Small Cell Lung Cancer, and Primary Peritoneal Carcinoma, among others.
PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Drug: PD-1 inhibitor
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 83
- Registration Number
- NCT06977074
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
- Conditions
- Advanced Solid TumorsColorectal CancerNon-Small Cell Lung Cancer
- Interventions
- Drug: Folinic Acid, Fluorouracil and Oxaliplatin/Irinotecan
- First Posted Date
- 2025-05-09
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Target Recruit Count
- 762
- Registration Number
- NCT06963502
- Locations
- 🇨🇳
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
🇨🇳Sun Yat-sen University Cancer Center, Shanghai, China
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-04-30
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 31
- Registration Number
- NCT06951841
- Locations
- 🇨🇳
The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
- Conditions
- Non-Small Cell Lung CancerNSCLCPDAC - Pancreatic Ductal AdenocarcinomaCRC (Colorectal Cancer)Metastatic Non-Small Lung Cell CancerMetastatic Colorectal Cancer (CRC)KRAS G12AKRAS G12CKRAS G12DKRAS G12S
- Interventions
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- TheRas, Inc., d/b/a BridgeBio Oncology Therapeutics
- Target Recruit Count
- 287
- Registration Number
- NCT06917079
- Locations
- 🇺🇸
Sarah Cannon Research Institute at Mary Crowley, Dallas, Texas, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸NEXT Oncology, San Antonio, Texas, United States
CtDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Diagnostic Test: Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay
- First Posted Date
- 2025-03-30
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 30
- Registration Number
- NCT06902272
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Comparative Study of Adjuvant Therapy for Postoperative Cervical Gastric-type Adenocarcinoma
- Conditions
- Gastric-type Endocervical AdenocarcinomaCervical Cancer
- Interventions
- Drug: paclitaxel and platinum
- First Posted Date
- 2025-03-11
- Last Posted Date
- 2025-03-17
- Target Recruit Count
- 238
- Registration Number
- NCT06870565
DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.
- Conditions
- Upper Tract Urothelial CancerBladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable
- Interventions
- Diagnostic Test: NGS test for DDR alterations
- First Posted Date
- 2025-02-11
- Last Posted Date
- 2025-02-11
- Target Recruit Count
- 135
- Registration Number
- NCT06820255
- Locations
- 🇮🇹
Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer
- Conditions
- Small Cell Lung Cancer Extensive StageSmall Cell Lung Cancer Recurrent
- Interventions
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Target Recruit Count
- 100
- Registration Number
- NCT06648200
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 112
- Registration Number
- NCT06623656
- Locations
- 🇺🇸
Weill Cornell Medicine, New York, New York, United States
Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC
- Conditions
- Head and Neck Squamous Cell CarcinomaHead and Neck Cancer
- Interventions
- Procedure: SurgeryRadiation: Adjuvant radiation
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 27
- Registration Number
- NCT06494943
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.